lymphocytes susceptible to an OFN effect on cell proliferation or EBV replication.
Epstein-Barr virus (EBV) is a human herpesvirus associated with Burkitt's lymphoma, nasopharyngeal carcinoma, and lymphoproliferative diseases in immunocompromised hosts (for reviews, see references 10 and 15). The virus efficiently transforms human B lymphocytes in vitro, establishing immortalized, proliferating lymphoblastoid cell lines (LCLs). Most transformed cells are not permissive of lytic virus replication. In these cells, the viral genome persists as a nuclear episome and expresses nine latent proteins and two small, nonpolyadenylated RNAs known as EBER 1 and EBER 2 (11, 13, 14) . The EBERs are the most abundant EBV-encoded RNAs and have been found in all EBVinfected lymphocytes (1, 2, 18) . The EBERs physically associate with the cellular La protein (12) and a newly described protein of unknown function named EBER-associated protein (24) . Despite extensive investigation, their function remains unknown.
The EBER RNAs are similar to the adenovirus VA RNAs in size, predicted secondary structure, transcription by RNA polymerase III, and La antigen association (19) . The VA RNAs are produced in large amounts during the late phase of adenovirus replication (23) and antagonize the antiviral effects of interferon (IFN) . IFN induces the double-stranded RNA-activated protein synthesis inhibitor (DAI), a kinase which is activated by viral replication. Activated DAI phosphorylates eukaryotic initiation factor 2 (eIF-2), preventing initiation of translation (20) . VAI RNA binds DAI, preventing its activation and permitting protein synthesis (11) . Adenovirus mutants without VA RNA genes are defective in viral replication because of DAI-mediated translational arrest in IFN-treated cells (16) . EBER 1 can partially substitute for the VA RNA genes in complementing the growth of adenovirus VA RNA deletion mutants (3) . Furthermore, EBER 1 RNA, synthesized in vitro, can bind DAI (4) and partially ameliorate the inhibition of protein synthesis by DAI in reticulocyte lysates (5) . Because of their similarity to VA RNAs, EBER RNAs could play a role in protecting EBV from IFN-mediated host defenses. However, EBERs are primarily nuclear in location (9) (14) . Since cell proliferation requires uninhibited protein synthesis, the natural IFN resistance of EBV-transformed B lymphocytes could be due to the EBERs. We therefore compared the growth of EBER-negative and EBER-positive LCLs in the presence of IFNs. Although EBV-transformed LCLs vary in growth rate (unpublished observations), there is no significant difference in the growth rate of EBERpositive and -negative LCLs overall (22) . IFN effects on the growth of LCLs with similar basal growth rates transformed by EBER-negative or -positive EBV could therefore be compared.
LCLs growing in the logarithmic phase were diluted to a density of 2 x 105/ml in RPMI medium with 10% fetal calf serum and plated in 96-well microtiter dishes. Recombinant human gamma interferon (IFN-y) (Sigma) or highly purified human IFN-a (Sigma) was added at concentrations from 0 to 1,000 U/ml. As shown in Fig. 1 (22) . Both cell lines demonstrate increased viral replication when treated with TPA (Fig. 2) . The higher level of EBV replicative-cycle gene expression is unaffected by IFN treatment (Fig. 2) . gp350, the major late glycoprotein of EBV, is produced in both cell lines, indicating that synthesis and processing of large complex EBV proteins required for infectious virus production are unaffected by IFN even in cells infected with EBER-negative virus. As expected, the titers of transforming EBV released from such IFN-treated cultures were similar to those from untreated cultures (see below).
IFN-a and IFN-y inhibit the proliferation of EBV-infected
B lymphocytes when added at the time of infection (14) . IFN-a also prevents the eventual outgrowth of EBV-transformed cells into LCLs (8) . This inhibition is a direct effect on the infected B lymphocytes and is not dependent on accessory cells. The IFN inhibitory effect is most pronounced during the first week after infection. The growth of established LCLs is not inhibited by IFN (data above and reference 8).
Because the EBERs may play a role in blocking IFNmediated inhibition of B-lymphocyte immortalization by EBV, the effect of IFN on transformation by EBER-positive and -negative EBV was compared. As described previously, LCLs are only partially permissive of viral replication and produce little free virus. To passage virus from LCLs, it is often necessary to cocultivate irradiated infected LCLs with target primary lymphocytes (22 Fig. 3 .
Both IFN-a and IFN--y had a reproducible inhibitory effect on the outgrowth of EBV-transformed B cells. EBERnegative virus was not more sensitive to this IFN antitransforming effect. Inclusion of IFN in the cell culture during the period of virus induction by TPA did not further affect the final number of transformants obtained (data not shown), confirming that neither IFN-a nor IFN-y has a significant effect on virus replication in cells infected with EBERnegative or -positive virus.
These experiments indicate that IFN inhibits transformation by a direct effect on the newly infected B lymphocyte and that EBER RNAs do not play a significant role in antagonizing IFN. Given this effect of IFN on newly infected cell outgrowth, the lack of an inhibitory IFN effect on EBV replication was surprising. To determine whether IFNs were capable of inducing an antiviral state (17) in EBV-infected LCLs, we examined the effect of IFN on VSV replication in these cells. Replication of VSV is highly sensitive to IFN treatment, and inhibition of VSV replication is a standard assay for the biological activity of IFN-a (17) . LCLs can be infected with VSV and permit VSV replication (7). EBERnegative and EBER-positive LCLs were infected with the Indiana serotype of VSV at a multiplicity of 10 PFU per cell. VSV was grown and purified as described previously (21) . After adsorption for 60 min at 37°C, the cells were washed 66, 1992 on August 27, 2017 by guest http://jvi.asm.org/ Downloaded from investigation of the normal physiological function of the recently described EBER-associated protein (24) .
